Contineum Therapeutics CTNM
NASDAQ CTNM
$12.99 -0.43 (-3.20%)
At close: Oct 1, 2026 · 4:00 PM EDT

Contineum Therapeutics (CTNM) Non Operating Interest Expenses (2023)

Updated

Contineum Therapeutics' Non Operating Interest Expenses came in at $208,000 for FY2023.

Analysis

Contineum Therapeutics (CTNM) Non Operating Interest Expenses (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 281.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -462.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -435.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 247.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Contineum Therapeutics 502.82 Mn 502.82 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 116,000.00
Mar 31, 2023 92,000.00
API Access

Contineum Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=CTNM&period=max&api_key=YOUR_API_KEY